Adult stem cell development company commencing clinical trials applicable to estimated $30 billion degenerative disease market place
BIG NEWS !!! 100 PERCENT SURVIVAL RATE IN ALL 7 PATIENTS !!! WOW !!
Pluristem Reports Preliminary Data from its COVID-19 Compassionate Use Program, Treating Seven Patients with Acute Respiratory Failure
e